Stem cell treatment for chronic lung diseases

Respiration

Volumn 85, Issue 3, 2013, Pages 179-192

  Tzouvelekis, Argyris ^a   Ntolios, Paschalis ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Asthma; Chronic lung diseases; Chronic obstructive pulmonary disease; Cystic fibrosis; Idiopathic pulmonary fibrosis; Mesenchymal stem cells

Indexed keywords

BIOLOGICAL MARKER;

ALVEOLAR EPITHELIAL PROGENITOR CELL; ASTHMA; CELL REGENERATION; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; FIBROSING ALVEOLITIS; HUMAN; IMMUNOMODULATION; LUNG ALVEOLUS EPITHELIUM CELL; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION; THERAPY EFFECT;

EID: 84873047703     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000346525     Document Type: Review

References (101)

1. Fuchs E, Segre JA: Stem cells: a new lease on life. Cell 2000; 100: 143-155.
2. Gomperts BN, Strieter RM: Stem cells and chronic lung disease. Annu Rev Med 2007; 58: 285-298.
3. Rankin S: Mesenchymal stem cells. Thorax 2012; 67: 565-566.
4. Crystal RG, Randell SH, Engelhardt JF, Voy-now J, Sunday ME: Airway epithelial cells: current concepts and challenges. Proc Am Thorac Soc 2008; 5: 772-777.
5. Huertas A, Palange P: Circulating endothelial progenitor cells and chronic pulmonary diseases. Eur Respir J 2011; 37: 426-431.
6. Siniscalco D, Sullo N, Maione S, Rossi F, D'Agostino B: Stem cell therapy: the great promise in lung disease. Ther Adv Respir Dis 2008; 2: 173-177.
7. Tzouvelekis A, Antoniadis A, Bouros D: Stem cell therapy in pulmonary fibrosis. Curr Opin Pulm Med 2011; 17: 368-373.
8. Kajstura J, Rota M, Hall SR, Hosoda T, D'Amario D, Sanada F, Zheng H, Ogorek B, Rondon-Clavo C, Ferreira-Martins J, Matsu-da A, Arranto C, Goichberg P, Giordano G, Haley KJ, Bardelli S, Rayatzadeh H, Liu X, Quaini F, Liao R, Leri A, Perrella MA, Loscal-zo J, Anversa P: Evidence for human lung stem cells. N Engl J Med 2011; 364: 1795-1806.
9. Rankin SM: Chemokines and adult bone marrow stem cells. Immunol Lett 2012; 145: 47-54.
10. Barnes PJ: Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med 2010; 7:e1000220.
11. Wang XX, Zhang FR, Shang YP, Zhu JH, Xie XD, Tao QM, Zhu JH, Chen JZ: Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idio-pathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007; 49: 1566-1571.
12. Zeng C, Wang X, Hu X, Chen J, Wang L: Au-tologous endothelial progenitor cells transplantation for the therapy of primary pulmonary hypertension. Med Hypotheses 2007; 68: 1292-1295.
13. Weiss DJ, Bertoncello I, Borok Z, Kim C, Pan-oskaltsis-Mortari A, Reynolds S, Rojas M, Stripp B, Warburton D, Prockop DJ: Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2011; 8: 223-272.
14. Wolf D, Wolf AM: Mesenchymal stem cells as cellular immunosuppressants. Lancet 2008; 371: 1553-1554.
15. Garcia-Gomez I, Elvira G, Zapata AG, Lama-na ML, Ramirez M, Castro JG, Arranz MG, Vicente A, Bueren J, Garcia-Olmo D: Mesen-chymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther 2010; 10: 1453-1468.
16. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S: Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 2000; 97: 13625-13630.
17. Kotton DN, Fine A: Lung stem cells. Cell Tissue Res 2008; 331: 145-156.
18. Gimble JM, Guilak F, Bunnell BA: Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther 2010; 1: 19.
19. Hong SJ, Traktuev DO, March KL: Therapeutic potential of adipose-derived stem cells in vascular growth and tissue repair. Curr Opin Organ Transplant 2010; 15: 86-91.
20. Kondo K, Shintani S, Shibata R, Murakami H, Murakami R, Imaizumi M, Kitagawa Y, Mu-rohara T: Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2009; 29: 61-66.
21. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multi-lineage potential of adult human mesenchy-mal stem cells. Science 1999; 284: 143-147.
22. Traktuev DO, Prater DN, Merfeld-Clauss S, Sanjeevaiah AR, Saadatzadeh MR, Murphy M, Johnstone BH, Ingram DA, March KL: Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. Circ Res 2009; 104: 1410-1420.
23. Arciniegas E, Neves CY, Carrillo LM, Zam-brano EA, Ramirez R: Endothelial-mesenchy-mal transition occurs during embryonic pulmonary artery development. Endothelium 2005; 12: 193-200.
24. Arciniegas E, Frid MG, Douglas IS, Stenmark KR: Perspectives on endothelial-to-mesen-chymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293:L1-L8.
25. Barbera JA, Peinado VI: Vascular progenitor cells in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2011; 8: 528-534.
26. Luan Y, Zhang ZH, Wei DE, Lu Y, Wang YB: Effects of autologous bone marrow mononu-clear cells implantation in canine model of pulmonary hypertension. Circ J 2012; 76: 977-985.
27. Peinado VI, Ramirez J, Roca J, Rodriguez-Roisin R, Barbera JA: Identification of vascular progenitor cells in pulmonary arteries of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2006; 34: 257-263.
28. Raoul W, Wagner-Ballon O, Saber G, Hulin A, Marcos E, Giraudier S, Vainchenker W, Adnot S, Eddahibi S, Maitre B: Effects of bone marrow-derived cells on monocrotaline-and hypoxia-induced pulmonary hypertension in mice. Respir Res 2007; 8: 8.
29. Zhu P, Huang L, Ge X, Yan F, Wu R, Ao Q: Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodelling. Int J Exp Pathol 2006; 87: 463-474.
30. Caramori G, Rigolin GM, Mazzoni F, Leprotti S, Campioni P, Papi A: Circulating endothelial stem cells are not decreased in pulmonary emphysema or COPD. Thorax 2010; 65: 554-555.
31. Fadini GP, Schiavon M, Cantini M, Baesso I, Facco M, Miorin M, Tassinato M, de Kreut-zenberg SV, Avogaro A, Agostini C: Circulating progenitor cells are reduced in patients with severe lung disease. Stem Cells 2006; 24: 1806-1813.
32. Huertas A, Testa U, Riccioni R, Petrucci E, Riti V, Savi D, Serra P, Bonsignore MR, Palange P: Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI. Respir Physiol Neuro-biol 2010; 170: 23-31.
33. Palange P, Testa U, Huertas A, Calabro L, An-tonucci R, Petrucci E, Pelosi E, Pasquini L, Satta A, Morici G, Vignola MA, Bonsignore MR: Circulating haemopoietic and endothe-lial progenitor cells are decreased in COPD. Eur Respir J 2006; 27: 529-541.
34. Hind M, Maden M: Is a regenerative approach viable for the treatment of COPD? Br J Pharmacol 2011; 163: 106-115.
35. Wang D, Morales JE, Calame DG, Alcorn JL, Wetsel RA: Transplantation of human embryonic stem cell-derived alveolar epithelial type II cells abrogates acute lung injury in mice. Mol Ther 2010; 18: 625-634.
36. Somers A, Jean JC, Sommer CA, Omari A, Ford CC, Mills JA, Ying L, Sommer AG, Jean JM, Smith BW, Lafyatis R, Demierre MF, Weiss DJ, French DL, Gadue P, Murphy GJ, Mostoslavsky G, Kotton DN: Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010; 28: 1728-1740.
37. Sommer CA, Stadtfeld M, Murphy GJ, Ho-chedlinger K, Kotton DN, Mostoslavsky G: Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009; 27: 543-549.
38. Sommer CA, Mostoslavsky G: The evolving field of induced pluripotency: recent progress and future challenges. J Cell Physiol 2013; 228: 267-275.
39. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
40. The IPFnet strategy: creating a comprehensive approach in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181: 527-528.
41. Wuyts WA, Agostini C, Antoniou K, Bouros D, Chambers R, Cottin V, Egan J, Lambrecht B, Lories R, Parfrey H, Prasse A, Robalo-Cor-deiro C, Verbeken E, Verschakelen J, Wells A, Verleden G: The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2012, E-pub ahead of print.
42. Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151.
43. Selman M, Pardo A: Idiopathic pulmonary fi-brosis: misunderstandings between epithelial cells and fibroblasts? Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 165-172.
44. Tzouvelekis A, Kouliatsis G, Anevlavis S, Bouros D: Serum biomarkers in interstitial lung diseases. Respir Res 2005; 6: 78.
45. Tzouvelekis A, Harokopos V, Paparountas T, Oikonomou N, Chatziioannou A, Vilaras G, Tsiambas E, Karameris A, Bouros D, Aidinis V: Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogen-esis. Am J Respir Crit Care Med 2007; 176: 1108-1119.
46. Bouros D, Antoniou KM: Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005; 26: 693-702.
47. Raghu G: Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials. Chest 2009; 136: 330-333.
48. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG: Mesen-chymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100: 8407-8411.
49. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham KL: Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33: 145-152.
50. Germano D, Blyszczuk P, Valaperti A, Kania G, Dirnhofer S, Landmesser U, Luscher TF, Hunziker L, Zulewski H, Eriksson U: Prom-inin-1/CD133+ lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 939-949.
51. Zhao F, Zhang YF, Liu YG, Zhou JJ, Li ZK, Wu CG, Qi HW: Therapeutic effects of bone marrow-derived mesenchymal stem cells en-graftment on bleomycin-induced lung injury in rats. Transplant Proc 2008; 40: 1700-1705.
52. Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, Boyd R, Trounson A: Human umbilical cord mesen-chymal stem cells reduce fibrosis of bleomy-cin-induced lung injury. Am J Pathol 2009; 175: 303-313.
53. Aguilar S, Scotton CJ, McNulty K, Nye E, Stamp G, Laurent G, Bonnet D, Janes SM: Bone marrow stem cells expressing keratino-cyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009; 4:e8013.
54. Kumamoto M, Nishiwaki T, Matsuo N, Kimu-ra H, Matsushima K: Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury. Eur Respir J 2009; 34: 740-748.
55. Lee SH, Jang AS, Kim YE, Cha JY, Kim TH, Jung S, Park SK, Lee YK, Won JH, Kim YH, Park CS: Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. Respir Res 2010; 11: 16.
56. Cargnoni A, Gibelli L, Tosini A, Signoroni PB, Nassuato C, Arienti D, Lombardi G, Al-bertini A, Wengler GS, Parolini O: Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplant 2009; 18: 405-422.
57. Spitalieri P, Quitadamo MC, Orlandi A, Guerra L, Giardina E, Casavola V, Novelli G, Saltini C, Sangiuolo F: Rescue of murine silica-induced lung injury and fibrosis by human embryonic stem cells. Eur Respir J 2012; 39: 446-457.
58. Sueblinvong V, Loi R, Eisenhauer PL, Bernstein IM, Suratt BT, Spees JL, Weiss DJ: Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med 2008; 177: 701-711.
59. Adcock IM, Caramori G, Barnes PJ: Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011; 81: 265-284.
60. Barnes PJ: Small airways in COPD. N Engl J Med 2004; 350: 2635-2637.
61. Barnes PJ: Emerging pharmacotherapies for COPD. Chest 2008; 134: 1278-1286.
62. Chilosi M, Poletti V, Rossi A: The pathogen-esis of COPD and IPF: distinct horns of the same devil? Respir Res 2012; 13: 3.
63. Shigemura N, Okumura M, Mizuno S, Imani-shi Y, Nakamura T, Sawa Y: Autologous transplantation of adipose tissue-derived stromal cells ameliorates pulmonary emphysema. Am J Transplant 2006; 6: 2592-2600.
64. Shigemura N, Okumura M, Mizuno S, Iman-ishi Y, Matsuyama A, Shiono H, Nakamura T, Sawa Y: Lung tissue engineering technique with adipose stromal cells improves surgical outcome for pulmonary emphysema. Am J Respir Crit Care Med 2006; 174: 1199-1205.
65. Zhen G, Liu H, Gu N, Zhang H, Xu Y, Zhang Z: Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front Biosci 2008; 13: 3415-3422.
66. Zhen G, Xue Z, Zhao J, Gu N, Tang Z, Xu Y, Zhang Z: Mesenchymal stem cell transplantation increases expression of vascular endothe-lial growth factor in papain-induced emphy-sematous lungs and inhibits apoptosis of lung cells. Cytotherapy 2010; 12: 605-614.
67. Katsha AM, Ohkouchi S, Xin H, Kanehira M, Sun R, Nukiwa T, Saijo Y: Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther 2011; 19: 196-203.
68. Schweitzer KS, Johnstone BH, Garrison J, Rush NI, Cooper S, Traktuev DO, Feng D, Adamowicz JJ, Van DM, Fisher AJ, Kamocki K, Brown MB, Presson RG Jr, Broxmeyer HE, March KL, Petrache I: Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med 2011; 183: 215-225.
69. Sala E, Villena C, Balaguer C, Rios A, Fernan-dez-Palomeque C, Cosio BG, Garcia J, Nog-uera A, Agusti A: Abnormal levels of circulating endothelial progenitor cells during exacerbations of COPD. Lung 2010; 188: 331-338.
70. Takahashi T, Suzuki S, Kubo H, Yamaya M, Kurosawa S, Kato M: Impaired endothelial progenitor cell mobilization and colony-forming capacity in chronic obstructive pulmonary disease. Respirology 2011; 16: 680-687.
71. Marsboom G, Pokreisz P, Gheysens O, Ver-meersch P, Gillijns H, Pellens M, Liu X, Col-len D, Janssens S: Sustained endothelial progenitor cell dysfunction after chronic hypox-ia-induced pulmonary hypertension. Stem Cells 2008; 26: 1017-1026.
72. Massaro GD, Massaro D: Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol 1996; 270:L305-L310.
73. McGowan S, Jackson SK, Jenkins-Moore M, Dai HH, Chambon P, Snyder JM: Mice bearing deletions of retinoic acid receptors demonstrate reduced lung elastin and alveolar numbers. Am J Respir Cell Mol Biol 2000; 23: 162-167.
74. Roth MD, Connett JE, D'Armiento JM, Fo-ronjy RF, Friedman PJ, Goldin JG, Louis TA, Mao JT, Muindi JR, O'Connor GT, Ramsdell JW, Ries AL, Scharf SM, Schluger NW, Sci-urba FC, Skeans MA, Walter RE, Wendt CH, Wise RA: Feasibility of retinoids for the treatment of emphysema study. Chest 2006; 130: 1334-1345.
75. Mao JT, Goldin JG, Dermand J, Ibrahim G, Brown MS, Emerick A, McNitt-Gray MF, Gj-ertson DW, Estrada F, Tashkin DP, Roth MD: A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med 2002; 165: 718-723.
76. Burke W: Genomics as a probe for disease biology. N Engl J Med 2003; 349: 969-974.
77. Stern RC: The diagnosis of cystic fibrosis. N Engl J Med 1997; 336: 487-491.
78. Pasyk S, Molinski S, Yu W, Eckford PD, Bear CE: Identification and validation of hits from high throughput screens for CFTR modulators. Curr Pharm Des 2012; 18: 628-641.
79. Pickering SJ, Minger SL, Patel M, Taylor H, Black C, Burns CJ, Ekonomou A, Braude PR: Generation of a human embryonic stem cell line encoding the cystic fibrosis mutation del-taF508, using preimplantation genetic diagnosis. Reprod Biomed Online 2005; 10: 390-397.
80. Wong AP, Keating A, Lu WY, Duchesneau P, Wang X, Sacher A, Hu J, Waddell TK: Identification of a bone marrow-derived epithelial-like population capable of repopulating injured mouse airway epithelium. J Clin Invest 2009; 119: 336-348.
81. Wong AP, Bear CE, Chin S, Pasceri P, Thompson TO, Huan LJ, Ratjen F, Ellis J, Rossant J: Directed differentiation of human pluripo-tent stem cells into mature airway epithelia expressing functional CFTRTR protein. Nat Biotechnol 2012; 30: 876-882.
82. Mou H, Zhao R, Sherwood R, Ahfeldt T, La-pey A, Wain J, Sicilian L, Izvolsky K, Musun-uru K, Cowan C, Rajagopal J: Generation of multipotent lung and airway progenitors from mouse ESCs and patient-specific cystic fibro-sis iPSCs. Cell Stem Cell 2012; 10: 385-397.
83. Barnes PJ: New drugs for asthma. Nat Rev Drug Discov 2004; 3: 831-844.
84. Barnes PJ: Intrinsic asthma: not so different from allergic asthma but driven by superanti-gens? Clin Exp Allergy 2009; 39: 1145-1151.
85. Barnes PJ: New therapies for asthma: is there any progress? Trends Pharmacol Sci 2010; 31: 335-343.
86. Bonfield TL, Koloze M, Lennon DP, Zuchows-ki B, Yang SE, Caplan AI: Human mesenchy-mal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am J Physiol Lung Cell Mol Physiol 2010; 299:L760-L770.
87. Cho KS, Roh HJ: Immunomodulatory effects of adipose-derived stem cells in airway allergic diseases. Curr Stem Cell Res Ther 2010; 5: 111-115.
88. Nemeth K, Keane-Myers A, Brown JM, Met-calfe DD, Gorham JD, Bundoc VG, Hodges MG, Jelinek I, Madala S, Karpati S, Mezey E: Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010; 107: 5652-5657.
89. Park HK, Cho KS, Park HY, Shin DH, Kim YK, Jung JS, Park SK, Roh HJ: Adipose-derived stromal cells inhibit allergic airway inflammation in mice. Stem Cells Dev 2010; 19: 1811-1818.
90. Goodwin M, Sueblinvong V, Eisenhauer P, Ziats NP, LeClair L, Poynter ME, Steele C, Rincon M, Weiss DJ: Bone marrow-derived mesenchymal stromal cells inhibit Th2-medi-ated allergic airways inflammation in mice. Stem Cells 2011; 29: 1137-1148.
91. Zhu JH, Wang XX, Zhang FR, Shang YP, Tao QM, Zhu JH, Chen JZ: Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Transplant 2008; 12: 650-655.
92. Perin EC, Silva GV, Henry TD, Cabreira-Hansen MG, Moore WH, Coulter SA, Herlihy JP, Fernandes MR, Cheong BY, Flamm SD, Traverse JH, Zheng Y, Smith D, Shaw S, Westbrook L, Olson R, Patel D, Gahreman-pour A, Canales J, Vaughn WK, Willerson JT: A randomized study of transendocardial injection of autologous bone marrow mononu-clear cells and cell function analysis in isch-emic heart failure (FOCUS-HF). Am Heart J 2011; 161: 1078-1087.
93. Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Fran-cescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarla-tos SI, Gordon DJ, Ebert RF, Kwak M, Moye LA, Simari RD: Effect of transendocardial delivery of autologous bone marrow mononu-clear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012; 307: 1717-1726.
94. Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye LA, Simari RD: LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J 2010; 37: 412-420.
95. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moye LA, Simari RD: Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011; 306: 2110-2119.
96. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, West-brook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moye LA, Simari RD: Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA 2012; 308: 2380-2389.
97. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W: A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocar-dial infarction. J Am Coll Cardiol 2009; 54: 2277-2286.
98. Ribeiro-Paes JT, Bilaqui A, Greco OT, Ruiz MA, Marcelino MY, Stessuk T, de Faria CA, Lago MR: Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. Int J Chron Obstruct Pulmon Dis 2011; 6: 63-71.
99. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease 2009. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011, www.goldcopd.com.
100. Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Kolios G, Kakagia D, Paspaliaris V, Kot-sianidis I, Froudarakis M, Bouros D: Stem cell therapy for idiopathic pulmonary fibro-sis: a protocol proposal. J Transl Med 2011; 9: 182.
101. Jones CP, Rankin SM: Bone marrow-derived stem cells and respiratory disease. Chest 2011; 140: 205-211.